Product Pipeline
In December 1998, GlaxoSmithKline's wholly owned subsidiary, GlaxoSmithKline Biologicals, announced Phase III results of a hepatitis B vaccine containing our MPL adjuvant. GlaxoSmithKline Biologicals developed this vaccine to address low or non-responding patients to GSK's current hepatitis B vaccine, Engerix-B. Engerix-B is currently the world's leading hepatitis B vaccine, with over 450 million doses administered worldwide. The new vaccine combines the antigen from Engerix-B with GSK's adjuvant, SBAS4, which contains our MPL adjuvant. The resulting vaccine has an increased immune potency, allowing two dose administration rather than three. We expect our partner, GSK, to file for European approval in early 2003.

Related News
05/12/2003 GSK's Fendrix containing Corixa's MPL adjuvant is filed for European regulatory approval
10/29/2001 Corixa and Wyeth Lederle Vaccines amend agreement
03/27/2000 Corixa and Wyeth Lederle Vaccines expand alliance
A business overview as well as information on Corixa's partners, management team, employment opportunities, and company contacts.
Corixa's near-term products and adjuvant for research applications.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.
Company reports, stockholder letter, events calendar, stock quote, analyst list, and materials request.
Current and archived company press releases.
Product pipeline, therapeutic areas of focus, products, technology platforms, and publications.